We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Testing Cancer Drugs in Children

Oct 1, 2001
Volume: 
15
Issue: 
10
  • Myelodysplastic Syndromes

A subcommittee of the Oncologic Drugs
Advisory Committee (ODAC) recently spent a day discussing the similarities and
differences between pediatric and adult hematologic malignancies. It was the
second session in a series intended to advise the Food and Drug Administration
(FDA) on how to apply its 1998 Pediatric Rule regarding the testing of cancer
drugs in children. The rule states that "there is a federal mandate to
perform pediatric studies if the indication under review for a marketing license
exists in children."

Subcommittee members and a panel of cancer specialists
addressed application of the rule in three areas: myeloid leukemia and
myelodysplastic syndrome, lymphoblastic leukemia, and lymphomas.

Ethical Dilemma

In his introductory comments, David G. Poplack, MD, professor
of pediatric oncology at Baylor College of Medicine, touched on a fundamental
issue of testing new drugs in children that are intended for adult use. He cited
acute lymphocytic leukemia (ALL), for which conventional cytotoxic therapy has a
good survival record in youngsters. If a new drug shows promise in adults, it
can be a challenge for pediatric clinical researchers to decide whether to test
it in children, he said.

"On the one hand, you can say, how is it ethical to
change the regimen?" said Dr. Poplack. "However, you can make a strong
argument to the contrary. We know that many curative therapies are associated
with toxicity. If you have something that is more specific—that may have fewer
toxicities—you may be ethically bound to study that drug vs the combination
therapies that may cure ALL but have high toxicities."

Although the FDA relies on ODAC for advice and guidance in
approving the marketing of cancer drugs and biologic agents, as well as other
issues relating to its regulatory responsibilities, the agency is under no
obligation to accept any ODAC recommendation.

Questions Posed by the FDA

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Related Articles

  • Implications of Mutation Profiling in Myeloid Malignancies—PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
  • Rigosertib May Benefit Some Patients with Myelodysplastic Syndromes
  • Therapeutic Vaccine Combination May Help Patients With Myelodysplastic Syndrome
  • Quizartinib Combination Highly Active in Myeloid Leukemias
  • Novel Treatment Approaches in Higher-Risk Myelodysplastic Syndromes

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.